The Use of Low-Dose Alemtuzumab in Pretreated B-Cell Chronic Lymphocytic Leukemia

Leukemia - United Kingdom
doi 10.1038/leu.2009.297
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

FDA Drug Approval Summary: Alemtuzumab as Single-Agent Treatment for B-Cell Chronic Lymphocytic Leukemia

Oncologist
Cancer ResearchMedicineOncology
2008English

Cytotoxic Lymphocytes in B-Cell Chronic Lymphocytic Leukemia

Annals of Hematology
MedicineHematology
1990English

First-Line Treatment of Chronic Lymphocytic Leukemia: Role of Alemtuzumab

OncoTargets and Therapy
OncologyPharmacology
2010English

Targeting the B Cell Receptor Pathway in Chronic Lymphocytic Leukemia

Leukemia and Lymphoma
Cancer ResearchOncologyHematology
2012English

Lack of Allelic Exclusion in B Cell Chronic Lymphocytic Leukemia

Journal of Experimental Medicine
MedicineAllergyImmunology
1997English

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Metformin Inhibits Cell Cycle Progression of B-Cell Chronic Lymphocytic Leukemia Cells

Oncotarget
Oncology
2015English

Cd160 Expression in B Chronic Lymphocytic Leukemia (B-Cll.).

International Journal of Advanced Research
2017English

ICOS Gene Polymorphisms in B-Cell Chronic Lymphocytic Leukemia in the Polish Population

Folia Histochemica et Cytobiologica
MedicineForensic MedicinePathologyHistology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy